There are 2789 resources available
As patients who progressed on both chemotherapy and immunotherapy for advanced disease
Presenter: Suresh Ramalingam
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Edward Garon
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast
Q&A
Presenter: Edward Garon
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast
Live Q&A and Closing
Presenter: Alessandra Curioni-Fontecedro
Session: Bristol Myers Squibb - I-O Revolution: New Perspectives in the Treatment of Thoracic Cancers
Resources:
Webcast
Full session recording
Presenter: Luis Paz-Ares
Session: Bristol Myers Squibb - I-O Revolution: New Perspectives in the Treatment of Thoracic Cancers
Resources:
Webcast
Dialogue: Live discussion and Q&A
Presenter: Peter Mohr
Session: Bristol Myers Squibb - Shaping Tomorrow Today: What Does the Future Hold for Melanoma?
Resources:
Webcast
Full session recording
Presenter: Caroline Robert
Session: Bristol Myers Squibb - Shaping Tomorrow Today: What Does the Future Hold for Melanoma?
Resources:
Webcast
NSCLC, metastatic 2
Presenter: Egbert F. Smit
Session: Expert selection 4
Resources:
Slides
Webcast
Head and neck cancers
Presenter: Kevin Harrington
Session: Expert selection 4
Resources:
Slides
Webcast
GI, colorectal 2
Presenter: Erika Martinelli
Session: Expert selection 4
Resources:
Slides
Webcast